Le Lézard
Classified in: Health
Subject: PER

Top Addiction Treatment Center In Washington D.C. Area Names New Chief Executive For Battle Against Opioid And Alcohol Epidemic


WALDORF, Md., Feb. 11, 2019 /PRNewswire/ -- Recovery Centers of America (RCA), an innovative, evidence-based addiction treatment company with six affordable, modern addiction treatment facilities, has appointed Lisa Dehorty, MP, MHC, as the Chief Executive Officer of the Maryland Center for Addiction Treatment (MCAT).

Dehorty has twenty years of leadership experience in the addiction treatment industry. In her new role, Dehorty will lead 168 employees and oversee all operations of the 140-bed addiction treatment facility. Dehorty's extensive experience encompasses a spectrum of roles in the delivery of addiction treatment from the admission process to leadership through all levels of care on the continuum. This wealth of experience led her to the Recovery Centers of America healthcare model.

"I loved what Recovery Centers of America was doing and the organization's vision, mission, and values aligned with my own on a personal level. I have found that the RCA model of care ? from the patient -friendly touches put into the facility designs to the excellence and spectrum of treatment services is an example of 'doing it right' for the patient," explained Dehorty.

Over 150,000 Americans died from alcoholism or substance abuse in 2017. Dehorty is firmly committed to being a part of the solution to this crisis. As the chief executive officer of Recovery Center of America's MCAT, Dehorty's dual focus will be on providing excellence in care and on assisting in the community with efforts to break down barriers to treatment so that people who are suffering from addiction will come to MCAT to get help.      

"Lisa has devoted her life to helping people with addiction and is an accomplished leader in this field. RCA is excited to have her skills and expertise in providing our MCAT patients the highest quality of care in the Washington D.C. and surrounding areas," said JP Christen, RCA Chief Operating Officer.

Dehorty has two master's degrees ? one in healthcare administration from St. Joseph's University and one in Psychology from Towson State University. She also holds a bachelor's degree in Psychology from Shepherd University.

The Maryland Center for Addiction Treatment in Waldorf, MD is a 140-bed facility providing medication-assisted detox, residential in-patient care, partial hospitalization, intensive outpatient, general outpatient care, and recovery support programs. MCAT's interventionist may also be utilized to assist in getting individuals in active addiction into treatment

Recovery Centers of America provides a comprehensive, evidence-based approach to addiction treatment. RCA is in-network with most insurance providers which makes our quality care affordable to families and reduces out of pocket expenses for those seeking treatment. Our Centers for addiction medicine are located in your neighborhood so it's easy for families to participate in the treatment process and to access care 24/7.

RCA provides patients with medication-assisted detox, residential in-patient care, partial hospitalization, intensive outpatient, general outpatient care, and medication-assisted treatment in some locations. RCA has 6 in-patient facilities in: Waldorf, MD; Earleville, MD; Devon, PA; Mays Landing, NJ; Danvers, MA; and Westminster, MA. Patients can also receive a full spectrum of outpatient treatment at centers in Waldorf, MD, Danvers, MA, Mays Landing, NJ, Vorhees, NJ, Devon, PA and at Trenton, NJ which is RCA's first Medication-Assisted Treatment Clinic.

MEDIA CONTACT:

Terri C. Malenfant/Director of Public Relations
Recovery Centers of America
[email protected]

SOURCE Recovery Centers of America


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: